GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

Health officials are reminding the public that antibiotics are ineffective against respiratory infections caused by viruses, ...

Arexvy is approved for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older and in individuals 50 through ...

Timely diagnosis of RSV is imperative for optimal patient management; by rapidly identifying RSV infection, health professionals can implement appropriate infection control measures while limiting ...

There's a chill in the air, students are back in school and summer's colors are fading—cold and flu season is nearly upon us.

Global Respiratory Syncytial Virus Therapeutics Market was valued at approximately USD 5.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.82% over the forecast ...

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

NHS bosses have urged Britons to get vaccinated this autumn to prevent a “tripledemic” of flu, covid-19 and respiratory ...

The Oregon Health Authority urges residents to stay up to date on vaccinations, as RSV season is difficult to forecast.

There are actions you can take to help protect yourself and loved ones from health risks caused by URIs. Stay home and away from others (including people you live with who are not sick) if you have ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

We are stronger when we are all protected against respiratory diseases,” said Dr. Tomas Aragon, public health officer for ...